z-logo
open-access-imgOpen Access
P7C3 inhibits GSK3β activation to protect dopaminergic neurons against neurotoxin-induced cell death in vitro and in vivo
Author(s) -
Chao Gu,
Yan Zhang,
Qingsong Hu,
Jiayuan Wu,
Haigang Ren,
ChunFeng Liu,
Guanghui Wang
Publication year - 2017
Publication title -
cell death and disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.482
H-Index - 111
ISSN - 2041-4889
DOI - 10.1038/cddis.2017.250
Subject(s) - substantia nigra , neurotoxin , microbiology and biotechnology , programmed cell death , gsk 3 , dopaminergic , chemistry , mptp , neuroprotection , mitochondrion , biology , apoptosis , biochemistry , phosphorylation , pharmacology , dopamine , endocrinology
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease. Although its pathogenesis remains unclear, mitochondrial dysfunction plays a vital role in the pathology of PD. P7C3, an aminopropyl carbazole, possesses a significant neuroprotective ability in several neurodegenerative disorders, including PD. Here, we showed that P7C3 stabilized mitochondrial membrane potential, reduced reactive oxygen species production, and inhibited cytochrome c release in MES23.5 cells (a dopaminergic (DA) cell line) exposed to 1-methyl-4-phenylpyridinium (MPP + ). In MES23.5 cells, P7C3 inhibited glycogen synthase kinase-3 beta (GSK3 β ) activation induced by MPP + . P7C3 also inhibited p53 activity and repressed Bax upregulation to protect cells from MPP + toxicity. In addition, the activation of p53 was significantly attenuated with the inhibition of GSK3 β activity by P7C3. Furthermore, P7C3 blocked GSK3 β and p53 activation in the midbrain, and prevented DA neuronal loss in the substantia nigra in 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine mice. Thus, our study demonstrates that P7C3 protects DA neurons from neurotoxin-induced cell death by repressing the GSK3 β -p53-Bax pathway both in vitro and in vivo , thus providing a theoretical basis for P7C3 in the potential clinical treatment of PD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here